ABSTRACT Introduction: In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1-expressing (tumor proportion score 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.
Introduction
Single-agent docetaxel is a U.S. Food and Drug Administration-approved choice for chemotherapy following progression on a platinum-based combination depending on improvement in survival, time to symptom deterioration, and pain, although response rates are generally low and the benefit is short-lived. 1 Nonetheless, docetaxel has become the standard comparator in multiple clinical trials, and improvements upon it have generally been marginal, with limited capture of quality of life (QoL) data. 2 Some tumors, including NSCLC, have been found to express the programmed death-ligand 1 (PD-L1), which enables them to exploit the programmed death 1 (PD-1):PD-L1 pathway to evade immune surveillance, thus allowing them to grow and proliferate unchecked. 3 The humanized monoclonal anti-PD-1 antibody pembrolizumab has shown significant efficacy as a monotherapy in patients with previously treated, advanced NSCLC with a PD-L1 tumor proportion score [TPS] greater than or equal to 1% in the KEYNOTE-010 study (N ¼ 1034; ClinicalTrials.gov, NCT01905657). 4 At a dose of 2 mg/kg, pembrolizumab was also found to improve overall survival compared with standard-of-care (docetaxel 75 mg/m 2 ; hazard ratio [HR] : 0.71, 95% confidence interval [CI] : 0.58-0.88, p ¼ 0.0008) in patients with PD-L1 TPS greater than or equal to 1% (10.4 months [95% CI: 9.4-11.9 months] versus 8.5 months [95% CI, 7.5-9.8 months]). 4 Lung indications for which pembrolizumab is currently approved include metastatic NSCLC with PD-L1 expression (TPS 1%) and disease progression on or after platinum-containing chemotherapy, metastatic NSCLC with high PD-L1 expression (TPS 50%) and no prior systemic chemotherapy, in combination with pemetrexed and carboplatin for previously untreated metastatic, nonsquamous NSCLC, and in combination with carboplatin and either paclitaxel or nab-paclitaxel for previously untreated metastatic, squamous NSCLC. [5] [6] [7] In addition to efficacy, the tolerability of treatment and impact on health-related quality of life (HRQoL) are very important considerations for patients with cancer. The effects of pembrolizumab and docetaxel on HRQoL were evaluated in the present study using three patientreported outcomes (PRO) instruments that have been widely used in phase III NSCLC trials: the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30 (C30), EORTC QLQ Lung Cancer 13 (EORTC QLQ-LC13), and the EuroQoL five dimensions, three-level questionnaire (EQ-5D-3L).
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Materials and Methods
Study Design and Participants
KEYNOTE-010 was an international, open-label, phase II/III study of pembrolizumab versus docetaxel in which 1034 patients with previously treated advanced NSCLC with PD-L1-expressing tumors and disease progression after platinum-containing systemic therapy were enrolled between August 28, 2013, and February 27, 2015. 4 The study design and primary efficacy and safety data are published elsewhere. 4 In brief, adult patients with a histologically or cytologically confirmed diagnosis of NSCLC, disease progression after 2 cycles or more of platinum-doublet chemotherapy, and PD-L1 expression on greater than or equal to 1% of tumor cells (i.e., TPS 1%) were randomized 1:1:1 to receive either pembrolizumab at a dose of 2 or 10 mg/kg intravenously every 3 weeks for a maximum of 24 months (i.e., 35 cycles) or docetaxel intravenously at a dose of 75 mg/m 2 every 3 weeks for the maximum number of cycles permitted by local regulatory authorities. 4 Tumor PD-L1 expression was assessed using formalin-fixed paraffin-embedded tissue at a central laboratory with the PD-L1 IHC 22C3 pharmDx immunohistochemistry assay (Dako, Carpinteria, California) and using the murine 22C3 anti-human PD-L1 antibody (Merck & Co., Inc., Kenilworth, New Jersey). 4, 12, 13 Patients were stratified according to level of PD-L1 expression by TPS (TPS 50% vs. TPS 1% to 49%), as well as Eastern Cooperative Oncology Group performance status (0 vs. 1) and geographic region of enrollment (East Asia vs. non-East Asia). 4 The study was conducted in accordance with the protocol, Good Clinical Practice guidelines, and the Declaration of Helsinki. All patients provided written informed consent.
HRQoL Objectives, Instruments, and Assessments
The pre-specified key analyses for HRQoL were mean change from baseline to week 12 in the EORTC QLQ-C30 global health status (GHS) score and time to deterioration (TTD) in an EORTC QLQ-LC13 composite endpoint of cough (question [Q]1), dyspnea (Q3-Q5), and chest pain (Q10). 14, 15 Traditional TTD was defined as the time to first onset of 10-point or more decrease from baseline in any one of these three symptoms (traditional deterioration). 16 True deterioration was defined as TTD in the EORTC QLQ-LC13 composite endpoint as described above with a confirmatory second, adjacent 10-point or more decrease from baseline (true deterioration).
Supportive HRQoL analyses included, but were not limited to proportion of patients who were improved, stable, or deteriorated for EORTC QLQ-C30 GHS/QoL score, functioning, and symptom scales at week 12 according to a 10-point or more change from baseline, and longitudinal score changes from baseline to week 12 in EORTC QLQ-C30 functioning and symptom scales and EORTC QLQ-LC13 symptom scales. 16 In this regard, improved was defined as a 10-point or greater increase in functioning scale scores or a 10-point or greater decrease in symptom scale scores, and deteriorated was defined as a 10-point or greater decrease in functioning scale scores or a 10-point or greater increase in symptom scale scores. Health status for economic modeling was assessed using the EQ-5D visual analog scale (VAS).
The HRQoL instruments were administered electronically by trained personnel and completed by the patients themselves in the following order: EQ-5D-3L, EORTC QLQ-C30, and EORTC QLQ-LC13. Each instrument was administered at the start of cycles 1, 2, 3, and 5, and every 4 cycles thereafter until discontinuation and 30-day safety assessment. Study sites were instructed to make every effort to ensure that administration of HRQoL instruments occurred before all other study procedures.
Statistical Analyses
EORTC QLQ-C30, EORTC QLQ-LC13, and EQ-5D-3L data were summarized according to the pre-specified exploratory analysis plan, using an HRQoL-specific full analysis set that comprised all randomized patients who received at least one dose of study medication and completed at least one PRO instrument. Analyses were performed for all patients (TPS 1%) and for those with tumor PD-L1 TPS 50% in each treatment arm.
PRO completion and compliance were calculated using the following definitions: PRO completion was defined as the proportion of patients who completed at least one valid questionnaire at each visit among the HRQoL full analysis set population. PRO compliance was defined as the proportion of patients who completed at least one valid questionnaire among those who were expected to complete each visit, thus excluding those patients from the denominator who were missing certain visits by design (e.g., due to death, discontinuation due to progression, discontinuation due to adverse event [AE], other discontinuation of treatment, translations not being available, or no visit being scheduled). Visits of treatment discontinuation and safety follow-up were mapped to different timepoints according to the actual visit time window.
Linear transformation was applied to standardize raw scores to a range of 0 to 100. 8 Mixed-effects models based on the missing-at-random assumption were used to assess changes in instrument score from baseline to week 12. Kaplan-Meier plots, stratified log-rank tests, and Cox proportional hazards models were used to assess the TTD in the EORTC QLQ-LC13 composite endpoint. Patients with no confirmed decrease from baseline were censored at the date of their last observation (right censoring rule). Descriptive analyses with multiple imputation based on the missing-at-random assumption yielded the proportion of patients with improved, stable, or deteriorated EORTC QLQ-C30 GHS/ QoL and functional and symptom scales.
Results
The findings for patients treated with pembrolizumab 2 mg/kg who had TPS 1% were the focus, as this may be the most clinically meaningful patient population given the original approved indication for pembrolizumab in second-line NSCLC. Data for all patients treated with pembrolizumab 10 mg/kg and those with TPS 50% for either pembrolizumab dose can be found in the supplementary materials.
PRO compliance was high across all three instruments (Supplementary Tables 1 through 3) . Compliance with EORTC QLQ-C30 at baseline was 96.1% and 93.2% for the pembrolizumab 2 mg/kg and docetaxel treatment arms, respectively. Compliance with EORTC QLQ-C30 at week 12 was 88.1% and 85.0% among patients treated with pembrolizumab (2 mg/kg) and docetaxel, respectively (Supplementary Table 1 ). Instrument completion frequencies decreased over time from baseline to week 36 as increasingly more patients discontinued the study due to disease progression, physician decision, AEs, or death. Findings were similar for the EORTC QLQ-LC13 (Supplementary Table 2 ) and EuroQoL-5D-3L instruments (Supplementary Table 3 ).
EORTC QLQ-C30
The baseline EORTC QLQ-C30 GHS/QoL score was similar across treatment arms and PD-L1 TPS groups (Table 1 and Supplementary Table 4) ; the mean score was 62.4 and 61.9 in patients treated with pembrolizumab (2 mg/kg) and docetaxel, respectively (Table 1 ). There was less worsening from baseline to week 12 for the pembrolizumab 2 mg/kg treatment arm (-1.2; 95% confidence interval [CI]: -3.70 to 1.37) than for the docetaxel arm (-3.8; 95% CI: -6.74 to -0.90); the improvement in GHS/QoL score for these patients compared to docetaxel was modest (difference in least squares [LS] means: 2.7 points; 95% CI: -1.1 to 6.4; two-sided nominal p ¼ 0.160) but not significant (Table 1 ). In addition, among patients who stayed on treatment and for whom PRO data were available beyond week 12, the modest improvement in EORTC QLQ-C30 GHS/QoL score with pembrolizumab remained relatively stable up to week 36 ( Supplementary Fig. 1) .
The proportion of patients with improvement in EORTC QLQ-C30 GHS/QoL score up to week 12 was larger for the pembrolizumab 2 mg/kg arm compared to docetaxel (28.7% and 24.9%, respectively) (Fig. 1) . In addition, the proportion of patients with deterioration in GHS/QoL score was smaller for the pembrolizumab 2 mg/kg arm than in the docetaxel arm (29.9% and 33.4%, respectively). With few exceptions, both the pembrolizumab 2 mg/kg ( Fig. 1 ) and 10 mg/kg (Supplementary Fig. 2A and Supplementary Fig. 3 ) treatment arms had a larger proportion of improved EORTC QLQ-C30 functioning and symptom domains and a smaller proportion of deteriorated functioning and symptom domains compared with docetaxel up to week 12 ( Fig. 1 and Supplementary Fig. 3 ).
Patients who received 2 mg/kg pembrolizumab had nominally significant improvement from baseline in EORTC QLQ-C30 insomnia, appetite loss, and constipation (i.e., 95% CI does not cross baseline value) ( Fig. 2A) . In contrast, patients receiving docetaxel reported nominally significant worsening from baseline in fatigue, nausea and vomiting, and diarrhea ( Fig. 2A) . Among patients without disease progression, there was a slight improvement in GHS/QoL score from baseline to week 12 for the pembrolizumab 2 mg/kg arm, but a worsening in QoL score for docetaxel (Table 2,  Supplementary Table 5 ). Among patients with disease progression, there was less worsening in GHS/QoL score from baseline to week 12 for pembrolizumab 2 mg/kg than for docetaxel ( Table 2, Supplementary Table 5) .
EORTC QLQ-LC13
There was no significant difference in "traditional" TTD in the QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain between pembrolizumab and docetaxel (Table 3, Supplementary Table 6 ); for patients in the pembrolizumab 2 mg/kg arm, the HR was 1.12 (95% CI: 0.92-1.37; two-sided nominal p ¼ 0.2711) compared to docetaxel (Table 3 ). Time to "true" deterioration was prolonged for the pembrolizumab 2 mg/kg dose group versus docetaxel (HR: 0.85 [0.69 to 1.06]; two-sided nominal p ¼ 0.1545) (Table 3) , and for both pembrolizumab dose groups versus docetaxel, regardless of TPS status, although the differences did not reach statistical significance in every instance (Supplementary Table 6 ).
Patients who received pembrolizumab 2 mg/kg had nominally significant improvements from baseline in symptoms of alopecia and chest pain, and notable improvement in coughing (Fig. 2B) . In contrast, patients in the docetaxel arm experienced nominally significant worsening from baseline in symptoms of alopecia, peripheral neuropathy, sore mouth, and dyspnea (Fig. 2B) . Compared with docetaxel, nominally significant improvements were observed for alopecia, peripheral neuropathy, and sore mouth among patients receiving pembrolizumab (2 mg/kg) (Fig. 2B) . Similar results were also observed for the pembrolizumab 10 mg/kg dose group ( Supplementary  Fig. 2B ).
EQ-5D
The results of the EQ-5D VAS analyses were consistent with those of the EORTC QLQ-C30 analyses (Supplementary Table 7 ). The baseline EQ-5D VAS score was similar across treatment arms and PD-L1 TPS groups, at 69.8 and 67.5 for the patients with PD-L1 TPS greater than or equal to 1% treated with pembrolizumab (2 mg/kg) and docetaxel, respectively. There was slight improvement from baseline to week 12 for the pembrolizumab 2 mg/kg treatment arm (1.5; 95% CI: -0.7 to 3.6) versus a reduction for the docetaxel arm (-1.3; 95% CI: -3.8 to 1.3); the improvement in VAS score for these patients compared to docetaxel was modest (difference in LS means: 2.7 points; 95% CI: -0.4 to 5.8) but not significant (Supplementary Table 7 ).
Discussion
To our knowledge, this is the first study to investigate the effect of pembrolizumab on HRQoL in patients with advanced NSCLC in the second-line setting. We found that treatment with pembrolizumab resulted in a numerically smaller reduction in the EORTC QLQ-C30 GHS/QoL score from baseline to week 12 (the estimated time at which more than half of patients in the docetaxel arm would have experienced disease progression). 1 Although the difference between treatment defined above), the pembrolizumab (2 mg/kg) treatment arm had a larger proportion of improved EORTC QLQ-C30 GHS/QoL scores and functioning and symptom domains and a smaller proportion of deteriorated scores compared with docetaxel. Nominally significant improvement was reported in many symptom domains with pembrolizumab, whereas nominally significant worsening was reported with docetaxel. Overall, the QoL analysis reinforces the objective response rate and progression-free survival results without showing any unexpected detrimental effect regarding the known safety profile of pembrolizumab. Long-term HRQoL data can be challenging to obtain because PRO completion rates drop off over the course of trials due to AEs, progression, and death (e.g., less than 10% of patients in the docetaxel arm completed PRO assessments at week 36). Following disease progression and discontinuation of treatment or the trial, the feasibility of continuing to administer PRO assessments that are tied to a clinic visit for receipt of study treatment is low. In this study, PRO data were collected post-progression by including an assessment at the 30-day safety follow-up visit because this visit followed treatment discontinuation primarily due to disease progression.
Although novel treatment approaches for NSCLC such as immune checkpoint inhibitors have brought with them improved overall survival compared to standardof-care chemotherapies, these findings must be weighed against any associated negative outcomes to ensure that any clinical gains do not come at the expense of intolerable reductions in HRQoL. 4, [17] [18] [19] [20] [21] [22] [23] [24] [25] There is currently no information in the literature regarding the HRQoL effects of pembrolizumab in NSCLC in the second-line setting. In the first-line setting, pembrolizumab monotherapy was associated with improved HRQoL and prolonged TTD among patients with advanced NSCLC with TPS greater than or equal to 50% and without sensitizing EGFR/ALK receptor tyrosine kinase (ALK) alterations (findings that concur with those reported here for patients with TPS 50% receiving 2 mg/kg pembrolizumab). 26 Additionally, pembrolizumab in combination with pemetrexed and platinum maintained or improved HRQoL over placebo plus pemetrexed and platinum among patients with metastatic nonsquamous NSCLC and without sensitizing EGFR/ ALK alterations, irrespective of PD-L1 expression. 27 Furthermore, HRQoL has been studied in patients with ipilimumab-refractory or -naïve advanced melanoma who received pembrolizumab in the KEYNOTE-002 (NCT01704287) and KEYNOTE-006 (NCT01866319) studies. 28, 29 The HRQoL findings of both were similar to those presented here, namely that pembrolizumab was well tolerated in patients with advanced melanoma, and either improved or maintained HRQoL and symptoms during treatment relative to either chemotherapy or ipilimumab. 28, 29 Similar findings were also reported in patients with previously treated advanced urothelial cancer who received pembrolizumab versus docetaxel, paclitaxel, or vinflunine in KEYNOTE-045 (NCT02256436). 30 There has been some exploration of the HRQoL effects of another anti-PD-1 agent -nivolumab -in advanced malignancies, including NSCLC. 17, 22, [31] [32] [33] In the CheckMate 017 study of nivolumab versus docetaxel in advanced NSCLC, the EQ-5D VAS instrument was used to evaluate patient-reported health status every 4 and 3 weeks for nivolumab and docetaxel, respectively, for the first 6 months on treatment; then every 6 weeks; and finally at two follow-up visits after treatment discontinuation. 33 From similar baseline scores, nivolumab treatment was associated with clinically and statistically significant improvements in health status from baseline relative to docetaxel. 33 Furthermore, the TTD (as measured by the Lung Cancer Symptom Scale, a global HRQoL instrument) was longer in the nivolumab arm than in those treated with docetaxel. 17, 33 Potential limitations of the current analysis include concern that the EORTC QLQ-LC13 instrument may not adequately reflect the experiences of patients who receive therapies developed after its development in 1994, the fact that the treatment was open-label (which could impact patients' perception of QoL), and the limited duration of follow-up. 34 The appropriateness of the HRQoL instruments may be mitigated in part because many commonly occurring symptoms attributed to immunotherapy, such as fatigue and gastrointestinal symptoms, could be captured using the EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires.
In conclusion, the present findings suggest that HRQoL and symptoms were either maintained or improved to a greater degree with 2 mg/kg pembrolizumab than with docetaxel in this population of patients with previously treated, PD-L1-expressing (TPS 1%) advanced NSCLC.
